(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 May 2009 (14.05.2009)

PCT

(10) International Publication Number
WO 2009/061271 A1

(51) International Patent Classification:
C07D 403/04 (2006.01) *A61P 11/00* (2006.01)
A61K 31/497 (2006.01) *A61P 19/00* (2006.01)
A61P 1/04 (2006.01) *C07D 401/14* (2006.01)

(21) International Application Number:
PCT/SE2008/051263

(22) International Filing Date:
5 November 2008 (05.11.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/985,713 6 November 2007 (06.11.2007) US

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **AINGE, Debra** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **CHAPMAN, David** [GB/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **LINDSJÖ, Martin** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **LÖNN, Hans** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **LUNDKVIST, Michael** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **MUNCK AF ROSENSCHÖLD, Magnus** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **NIKITIDIS, Antonios** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **PAVEY, John** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB).

(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

WO 2009/061271 A1

(54) Title: SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE

(57) Abstract: The invention provides certain novel 6-heteroaryl-5-methyl-3- oxo-4- [3 (trif luoromethyl) phenyl] -3,4-dihydropyrazine-2- carboxamide derivatives and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitord of human neutrophil elastase.